로딩 중…
StockDiggingStockDigging

Haemonetics Corporation

HAE· NYSE
$74.09+1.87%
2026-06-18

Price Chart

Haemonetics Corporation+5.75%

Financials

※ FY = Fiscal Year

Investment Metrics(as of 2026-06-18)

MetricValue
Size
Market Cap$3.37B
Revenue$1.33B
Net Income$97M
Total Assets$2.40B
Net Assets$796M
Employees3,023
Value
P/E34.60x
P/B4.23x
P/S2.52x
EV/EBITDA12.87x
FCF Yield7.73%
Profitability
ROE12.22%
ROA4.06%
Op. Margin18.15%
Revenue Growth4.76%
Earnings Growth-134.75%
Financial Health
Debt Ratio200.87%
Total Debt$1.22B
FCF$260M
Cash$245M
Current Ratio2.95x
Net Debt/EBITDA2.90x
Performance
1Y Return5.75%
1M Return30.33%
From 52W High-15.15%
1Y MDD-40.06%
Trading
Volume493,068 shares
Trading Value$36M
Per Share
EPS$3.75
BPS$19.48

Company Info

CEO Mr. Christopher A. Simon
Employees 3,023
HQ Boston, United States

Haemonetics Corporation, a medical technology company, provides a suite of hospital technologies solutions in the United States and internationally. The company offers automated plasma collection systems, donor management software, and supporting software solutions, including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system and Donor360 tools. It also provides treatment in electrophysiology, critical care, neurocritical care, trauma, burn surgery, spine surgery, and cancer surgery; SavvyWire, a sensor-guided 3-in-1 guidewire for TAVR procedures; and OptoWire, a pressure guidewire that measures fractional flow reserve and diastolic pressure ratio, as well as fiber optic sensor solutions used in medical devices and other critical industrial applications. In addition, the company offers hospital products comprising TEG and HAS hemostasis analyzer systems that provide a comprehensive assessment of a patient's overall hemostasis; and TEG Manager software, which connects various TEG analyzers throughout the hospital, providing clinicians remote access to active and historical test results that inform treatment decisions. Further, it provides Cell Saver Elite +, an autologous blood recovery system for cardiovascular, orthopedic, trauma, transplant, vascular, obstetrical, and gynecological surgeries; and VASCADE closure products comprising VASCADE 5F, VASCADE 6/7F, VASCADE MVP XL, and VASCADE MVP, a technology platform which offers catheter-based delivery system and leverages the natural clot-inducing properties of collagen. The company sells its products through direct sales force, independent distributors, clinical specialists, and sales representatives. Haemonetics Corporation was founded in 1971 and is headquartered in Boston, Massachusetts.